Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.24
STXS's Cash to Debt is ranked lower than
82% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.41 vs. STXS: 0.24 )
Ranked among companies with meaningful Cash to Debt only.
STXS' s 10-Year Cash to Debt Range
Min: 0.16  Med: 0.91 Max: N/A
Current: 0.24
Equity to Asset -0.67
STXS's Equity to Asset is ranked lower than
96% of the 170 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. STXS: -0.67 )
Ranked among companies with meaningful Equity to Asset only.
STXS' s 10-Year Equity to Asset Range
Min: -1.07  Med: 0.00 Max: 0.82
Current: -0.67
-1.07
0.82
F-Score: 4
Z-Score: -27.22
M-Score: -1.95
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -12.63
STXS's Operating margin (%) is ranked lower than
78% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.42 vs. STXS: -12.63 )
Ranked among companies with meaningful Operating margin (%) only.
STXS' s 10-Year Operating margin (%) Range
Min: -113273.68  Med: -101.62 Max: -15.38
Current: -12.63
-113273.68
-15.38
Net-margin (%) -11.60
STXS's Net-margin (%) is ranked lower than
75% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.58 vs. STXS: -11.60 )
Ranked among companies with meaningful Net-margin (%) only.
STXS' s 10-Year Net-margin (%) Range
Min: -112942.11  Med: -122.45 Max: -14.86
Current: -11.6
-112942.11
-14.86
ROA (%) -16.25
STXS's ROA (%) is ranked lower than
79% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.52 vs. STXS: -16.25 )
Ranked among companies with meaningful ROA (%) only.
STXS' s 10-Year ROA (%) Range
Min: -217.44  Med: -70.82 Max: -18.93
Current: -16.25
-217.44
-18.93
ROC (Joel Greenblatt) (%) -92.45
STXS's ROC (Joel Greenblatt) (%) is ranked lower than
82% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.82 vs. STXS: -92.45 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
STXS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6149.14  Med: -578.47 Max: -77.3
Current: -92.45
-6149.14
-77.3
Revenue Growth (3Y)(%) -37.40
STXS's Revenue Growth (3Y)(%) is ranked lower than
96% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. STXS: -37.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
STXS' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -14.85 Max: 218.5
Current: -37.4
0
218.5
EBITDA Growth (3Y)(%) -76.40
STXS's EBITDA Growth (3Y)(%) is ranked lower than
99% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.70 vs. STXS: -76.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
STXS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -76.4  Med: -33.95 Max: 19.6
Current: -76.4
-76.4
19.6
EPS Growth (3Y)(%) -63.80
STXS's EPS Growth (3Y)(%) is ranked lower than
98% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.70 vs. STXS: -63.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
STXS' s 10-Year EPS Growth (3Y)(%) Range
Min: -63.8  Med: -28.30 Max: 17.2
Current: -63.8
-63.8
17.2
» STXS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

STXS Guru Trades in Q2 2013

Jim Simons 48,842 sh (-16.99%)
» More
Q3 2013

STXS Guru Trades in Q3 2013

Jim Simons Sold Out
» More
Q4 2014

STXS Guru Trades in Q4 2014

Jim Simons 35,400 sh (New)
» More
Q1 2015

STXS Guru Trades in Q1 2015

Charles Brandes 40,000 sh (New)
Jim Simons 157,000 sh (+343.50%)
» More
» Details

Insider Trades

Latest Guru Trades with STXS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 0.73
STXS's P/S is ranked higher than
87% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.84 vs. STXS: 0.73 )
Ranked among companies with meaningful P/S only.
STXS' s 10-Year P/S Range
Min: 0.15  Med: 3.24 Max: 35.43
Current: 0.73
0.15
35.43
EV-to-EBIT -48.26
STXS's EV-to-EBIT is ranked lower than
208% of the 117 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.59 vs. STXS: -48.26 )
Ranked among companies with meaningful EV-to-EBIT only.
STXS' s 10-Year EV-to-EBIT Range
Min: -13.5  Med: -6.65 Max: -1.4
Current: -48.26
-13.5
-1.4
Current Ratio 1.13
STXS's Current Ratio is ranked lower than
89% of the 175 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.54 vs. STXS: 1.13 )
Ranked among companies with meaningful Current Ratio only.
STXS' s 10-Year Current Ratio Range
Min: 0.61  Med: 1.15 Max: 5.72
Current: 1.13
0.61
5.72
Quick Ratio 0.76
STXS's Quick Ratio is ranked lower than
89% of the 175 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.63 vs. STXS: 0.76 )
Ranked among companies with meaningful Quick Ratio only.
STXS' s 10-Year Quick Ratio Range
Min: 0.47  Med: 0.90 Max: 5.39
Current: 0.76
0.47
5.39
Days Inventory 244.73
STXS's Days Inventory is ranked lower than
85% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 129.36 vs. STXS: 244.73 )
Ranked among companies with meaningful Days Inventory only.
STXS' s 10-Year Days Inventory Range
Min: 115.43  Med: 217.04 Max: 10772.06
Current: 244.73
115.43
10772.06
Days Sales Outstanding 78.04
STXS's Days Sales Outstanding is ranked lower than
70% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.83 vs. STXS: 78.04 )
Ranked among companies with meaningful Days Sales Outstanding only.
STXS' s 10-Year Days Sales Outstanding Range
Min: 40.76  Med: 93.97 Max: 8375.79
Current: 78.04
40.76
8375.79

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.23
STXS's Price/Median PS Value is ranked higher than
98% of the 144 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.27 vs. STXS: 0.23 )
Ranked among companies with meaningful Price/Median PS Value only.
STXS' s 10-Year Price/Median PS Value Range
Min: 0.06  Med: 1.04 Max: 10.83
Current: 0.23
0.06
10.83
Earnings Yield (Greenblatt) (%) -2.06
STXS's Earnings Yield (Greenblatt) (%) is ranked lower than
72% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. STXS: -2.06 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
STXS' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -19.3  Med: 0.00 Max: 0
Current: -2.06
-19.3
0

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:RJR1.Germany,
Stereotaxis Inc was incorporated in Delaware on June 1990. The Company designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. The Niobe system is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, efficient procedures and reduced x-ray exposure. The core components of the Niobe system have received regulatory clearance in the U.S., Canada Europe, and various other countries. In addition to the Niobe system and its components, the Company also has developed the Odyssey Solution, which consolidates the multiple sources of diagnostic and imaging information found in the interventional lab into a large-screen user interface with single mouse control, which could be connected via a private network line to other interventional labs or to a remote clinical call center. The system also features a remote viewing and recording capability, called Odyssey Cinema, which simultaneously captures procedure data from multiple sources. The tool includes an archiving capability that would allow clinicians to store and replay entire procedures or segments of procedures. This information could be accessed from locations throughout the hospital local area network and over the global Odyssey network providing physicians with a tool for clinical collaboration, remote consultation and training. The Company operates mainly in the U.S., Europe and Asia and it continues to sell its products both within and outside of the U.S. It markets its products in the U.S and internationally through a direct sales force of senior sales specialists, distributors and sales agents, supported by account managers and clinical specialists that provide training, clinical support, and other services to its customers. The markets for medical devices are intensely competitive and are characterized by rapid technological advances, frequent new product introductions, evolving industry standards and price erosion. It faces competition from companies that are developing new approaches and products for use in interventional procedures, including robotic approaches that are directly competitive with its technology. It also faces competition from companies who currently market or are developing drugs, gene or cellular therapies to treat the conditions for which the Company's products are intended.
» More Articles for STXS

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: NBN, EMMS, STXS, FOE, NVTL May 21 2012 
comment on STXS Aug 20 2011 
Stereotaxis Inc. (STXS) CEO Michael P Kaminski buys 2,800 Shares Jan 04 2011 
Stereotaxis Inc. Reports Operating Results (10-Q) Nov 05 2010 
Stereotaxis Inc. (STXS) CEO Michael P Kaminski buys 2,500 Shares May 11 2010 
Stereotaxis Inc. (STXS) CFO Daniel J Johnston buys 10,000 Shares May 10 2010 
Stereotaxis Inc. Reports Operating Results (10-Q) May 07 2010 
Stereotaxis Inc. Reports Operating Results (10-Q) Nov 06 2009 
Stereotaxis Inc. (STXS) CEO Michael P Kaminski buys 1,410 Shares Sep 03 2009 
Stereotaxis Inc. Reports Operating Results (10-Q) Aug 07 2009 

More From Other Websites
Stereotaxis Reports 2015 Second Quarter Financial Results Aug 04 2015
Q2 2015 Stereotaxis Inc Earnings Release - Before Market Open Aug 04 2015
STEREOTAXIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 04 2015
6:38 am Stereotaxis reports Q2 results Aug 04 2015
Stereotaxis Reports 2015 Second Quarter Financial Results Aug 04 2015
Stereotaxis to Report Second Quarter 2015 Financial Results on August 4, 2015 Jul 28 2015
Stereotaxis to Report Second Quarter 2015 Financial Results on August 4, 2015 Jul 28 2015
Takatsuki General Hospital Performs First Procedure With Stereotaxis Niobe(R) ES Technology in Japan Jul 08 2015
Takatsuki General Hospital Performs First Procedure With Stereotaxis Niobe(R) ES Technology in Japan Jul 08 2015
Stereotaxis to Present at Cantor Fitzgerald Inaugural Healthcare Conference in New York on July 8,... Jul 02 2015
Stereotaxis to Present at Cantor Fitzgerald Inaugural Healthcare Conference in New York on July 8,... Jul 02 2015
Edited Transcript of STXS earnings conference call or presentation 6-May-15 8:30pm GMT Jun 22 2015
STEREOTAXIS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 04 2015
STEREOTAXIS, INC. Financials May 19 2015
Stereotaxis to Present New Clinical Evidence and Product Innovations at Heart Rhythm 2015 in Boston May 13 2015
Stereotaxis to Present New Clinical Evidence and Product Innovations at Heart Rhythm 2015 in Boston May 13 2015
10-Q for Stereotaxis, Inc. May 09 2015
STEREOTAXIS, INC. Files SEC form 10-Q, Quarterly Report May 07 2015
Stereotaxis Inc Earnings Call scheduled for 4:30 pm ET today May 06 2015
STEREOTAXIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK